Skip to main content
Search
Main content
Nat Commun
Published

Hyperphosphorylated tau self-assembles into amorphous aggregates eliciting TLR4-dependent responses.

Authors

Jonathan X Meng, Yu Zhang, Dominik Saman, Arshad M Haider, Suman De, Jason C Sang, Karen Brown, Kun Jiang, Jane Humphrey, Linda Julian, Eric Hidari, Steven F Lee, Gabriel Balmus, R Andres Floto, Clare E Bryant, Justin L P Benesch, Yu Ye, David Klenerman

Abstract

Soluble aggregates of the microtubule-associated protein tau have been challenging to assemble and characterize, despite their important role in the development of tauopathies. We found that sequential hyperphosphorylation by protein kinase A in conjugation with either glycogen synthase kinase 3β or stress activated protein kinase 4 enabled recombinant wild-type tau of isoform 0N4R to spontaneously polymerize into small amorphous aggregates in vitro. We employed tandem mass spectrometry to determine the phosphorylation sites, high-resolution native mass spectrometry to measure the degree of phosphorylation, and super-resolution microscopy and electron microscopy to characterize the morphology of aggregates formed. Functionally, compared with the unmodified aggregates, which require heparin induction to assemble, these self-assembled hyperphosphorylated tau aggregates more efficiently disrupt membrane bilayers and induce Toll-like receptor 4-dependent responses in human macrophages. Together, our results demonstrate that hyperphosphorylated tau aggregates are potentially damaging to cells, suggesting a mechanism for how hyperphosphorylation could drive neuroinflammation in tauopathies.

PMID:35577786 | DOI:10.1038/s41467-022-30461-x

UK DRI Authors

Gabriel Balmus

Prof Gabriel Balmus

Group Leader

Identifying genetic and environmental factors involved in DNA damage, neurodegeneration and ageing in neurons

Prof Gabriel Balmus
David Klenerman

Prof Sir David Klenerman

Group Leader

Determining how protein clumps form, damage the brain and change as the different neurodegenerative diseases develop to know which ones to target for therapies

Prof Sir David Klenerman